Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Inhibition of iron uptake is responsible for differential sensitivity to V-ATPase inhibitors in several cancer cell lines.

Straud S, Zubovych I, De Brabander JK, Roth MG.

PLoS One. 2010 Jul 16;5(7):e11629. doi: 10.1371/journal.pone.0011629.

2.

Increased production of reactive oxygen species by the vacuolar-type (H(+))-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells.

Yokomakura A, Hong J, Ohuchi K, Oh SE, Lee JY, Mano N, Takahashi T, Hwang GW, Naganuma A.

J Toxicol Sci. 2012;37(5):1045-8.

3.

V-ATPase inhibitors and implication in cancer treatment.

Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JM, García-García A.

Cancer Treat Rev. 2009 Dec;35(8):707-13. doi: 10.1016/j.ctrv.2009.08.003. Epub 2009 Sep 15. Review.

PMID:
19758758
4.

V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.

Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E.

Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14.

5.

The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells.

Capecci J, Forgac M.

J Biol Chem. 2013 Nov 8;288(45):32731-41. doi: 10.1074/jbc.M113.503771. Epub 2013 Sep 26.

6.

Archazolid and apicularen: novel specific V-ATPase inhibitors.

Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, Zeeck A, Wieczorek H.

BMC Biochem. 2005 Aug 4;6:13.

7.

Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.

Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, Kubisch-Dohmen R, Liebl J, Trauner D, Menche D, Vollmar AM.

Cancer Res. 2015 Jul 15;75(14):2863-74. doi: 10.1158/0008-5472.CAN-14-2097. Epub 2015 May 27.

8.

Mitoferrin-2-dependent mitochondrial iron uptake sensitizes human head and neck squamous carcinoma cells to photodynamic therapy.

Hung HI, Schwartz JM, Maldonado EN, Lemasters JJ, Nieminen AL.

J Biol Chem. 2013 Jan 4;288(1):677-86. doi: 10.1074/jbc.M112.422667. Epub 2012 Nov 7.

9.

Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer.

Hernandez A, Serrano-Bueno G, Perez-Castineira JR, Serrano A.

Curr Pharm Des. 2012;18(10):1383-94. Review.

PMID:
22360554
10.

Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion.

Michel V, Licon-Munoz Y, Trujillo K, Bisoffi M, Parra KJ.

Int J Cancer. 2013 Jan 15;132(2):E1-10. doi: 10.1002/ijc.27811. Epub 2012 Sep 21.

11.

ZT-25, a new vacuolar H(+)-ATPase inhibitor, induces apoptosis and protective autophagy through ROS generation in HepG2 cells.

Lu Y, Zhang R, Liu S, Zhao Y, Gao J, Zhu L.

Eur J Pharmacol. 2016 Jan 15;771:130-8. doi: 10.1016/j.ejphar.2015.12.026. Epub 2015 Dec 12.

PMID:
26689625
12.

Synthesis and V-ATPase inhibition of simplified lobatamide analogues.

Shen R, Lin CT, Bowman EJ, Bowman BJ, Porco JA Jr.

Org Lett. 2002 Sep 5;4(18):3103-6.

PMID:
12201727
13.

Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.

Lebreton S, Jaunbergs J, Roth MG, Ferguson DA, De Brabander JK.

Bioorg Med Chem Lett. 2008 Nov 15;18(22):5879-83. doi: 10.1016/j.bmcl.2008.07.003. Epub 2008 Jul 5.

14.

Iejimalides A and B inhibit lysosomal vacuolar H+-ATPase (V-ATPase) activity and induce S-phase arrest and apoptosis in MCF-7 cells.

McHenry P, Wang WL, Devitt E, Kluesner N, Davisson VJ, McKee E, Schweitzer D, Helquist P, Tenniswood M.

J Cell Biochem. 2010 Mar 1;109(4):634-42. doi: 10.1002/jcb.22438.

PMID:
20039309
15.

pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines.

Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ.

Biochem Pharmacol. 1999 May 1;57(9):1037-46.

PMID:
10796074
16.

Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection.

Müller KH, Spoden GA, Scheffer KD, Brunnhöfer R, De Brabander JK, Maier ME, Florin L, Muller CP.

Antimicrob Agents Chemother. 2014 May;58(5):2905-11. doi: 10.1128/AAC.02284-13. Epub 2014 Mar 10.

17.
18.

The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1.

Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, Wagner E, Müller R, Scita G, Vollmar AM.

Cancer Res. 2012 Nov 15;72(22):5976-87. doi: 10.1158/0008-5472.CAN-12-1772. Epub 2012 Sep 17.

19.

Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry.

Johnson RM, Allen C, Melman SD, Waller A, Young SM, Sklar LA, Parra KJ.

Anal Biochem. 2010 Mar 15;398(2):203-11. doi: 10.1016/j.ab.2009.12.020. Epub 2009 Dec 14.

20.

The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma.

Morimura T, Fujita K, Akita M, Nagashima M, Satomi A.

Pediatr Surg Int. 2008 Oct;24(10):1087-94. doi: 10.1007/s00383-008-2229-2.

PMID:
18712525

Supplemental Content

Support Center